Infliximab-associated psoriasis in children with crohn's disease may require withdrawal of anti-tumor necrosis factor therapy

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages

  Broge, Tangra ^a   Nguyen, Nam ^a   Sacks, Alan ^b   Davis, Michael ^b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b Children's Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE;

ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ANTIBIOTIC THERAPY; ANUS FISTULA; CASE REPORT; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE INTESTINE; LETTER; MALE; MONOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; SMALL INTESTINE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; MALE; PROGNOSIS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84876350374     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182802c93     Document Type: Letter

References (14)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
3. Erratum in N Engl J Med. 2006;354:2200.
4. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. Drugs Dermatol. 2009;8: 546-559.
5. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63:149-155.
6. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
7. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100-108.
8. Costa-Romero M, Coto-Segura P, Suarez-Saavedra, et al. Guttate Psoriasis Induced by Infliximab in a Child with Crohn's Disease. Inflamm Bowel Dis. 2008;10:1462-1463.
9. Hiremath G, Duffy L, Leibowitz I. Infliximabinduced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:230-232.
10. Baumgart DC, Grittner U, Steingräber A, et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512-2520.
11. Robinson D Jr, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006; 22:989-1000.
12. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferonalpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081-1088.
13. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012; 90:636-647.
14. Toussirot E, Houvenagel E, Goëb V, et al. Development of inflammatory bowel disease during anti- TNF-a therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine. 2012;79: 457-463.